As concerns about AI security, risk, and compliance continue to escalate, practical solutions remain elusive. While NIST released NIST-AI-600-1, Artificial Intelligence Risk Management Framework: Generative Artificial Intelligence Profile on July 26, 2024, most organizations are just beginning to digest and implement its guidance, with the formation of internal AI Councils as a first step in … Read more
By Brad Sorensen, CFA NASDAQ:MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a preclinical-stage pharmaceutical company that is about to be a clinical-stage company focused on the development and commercialization of a new molecular synthetic cannabinoid analog for the treatment of adult patients with neuropathic pain as well as anxiety and cognitive … Read more
By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Phase 3 FLASH2 Trial of HyBryte in CTCL is Underway On December 16, 2024, Soligenix, Inc. (NASDAQ:SNGX) announced that patient enrollment has opened up for the confirmatory Phase 3 FLASH2 (Fluorescent Light Activated Synthetic Hypericin 2) trial of HyBryte in patients with … Read more
By Thomas Kerr, CFA NASDAQ:CTSO READ THE FULL CTSO RESEARCH REPORT On December 9, 2024, CytoSorbents (NASDAQ:CTSO) announced a shareholder friendly anticipated Rights Offering which is expected to substantially increase its liquidity position. Investors who own or have bought CTSO stock by the close of trading on Friday, December 13, 2024 will be considered stockholders … Read more
A squad of fully armed soldiers follow closely behind a Humvee armoured vehicle, cautiously advancing through the ruins of an urban battlefield. About a kilometre ahead of them in the sky, a small drone hovers in place. Suddenly, one soldier lets out a scream, clutching his eyes with both hands as smoke curls between his … Read more